Vir Biotechnology (VIR) Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VIR shares.
View VIR analyst ratings or view top-rated stocks.

6 equities research analysts have issued 1 year price objectives for Vir Biotechnology's shares. Their VIR share price forecasts range from $27.00 to $100.00. On average, they predict the company's stock price to reach $49.75 in the next twelve months. This suggests a possible upside of 92.1% from the stock's current price.
View analysts price targets for VIR or view top-rated stocks among Wall Street analysts.

Vir Biotechnology's stock was trading at $25.31 on January 1st, 2023. Since then, VIR stock has increased by 2.3% and is now trading at $25.90.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our VIR earnings forecast.

Vir Biotechnology, Inc. (NASDAQ:VIR) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.20. The business earned $63 million during the quarter, compared to the consensus estimate of $50.10 million. The company's revenue was down 94.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.93 earnings per share.

ETFs with the largest weight of Vir Biotechnology (NASDAQ:VIR) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), iShares Genomics Immunology and Healthcare ETF (IDNA), ALPS Medical Breakthroughs ETF (SBIO), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Hartford Multifactor Small Cap ETF (ROSC), SPDR S&P Biotech ETF (XBI) and ETC 6 Meridian Small Cap Equity ETF (SIXS).

7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees.

(VIR) raised $149 million in an initial public offering on Friday, October 11th 2019. The company issued 7,100,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO.

Vir Biotechnology trades on the NASDAQ under the ticker symbol "VIR."

Vir Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional shareholders include SB Investment Advisers UK Ltd. (13.67%), BlackRock Inc. (10.42%), Temasek Holdings Private Ltd (4.34%), State Street Corp (4.02%), Baillie Gifford & Co. (2.98%) and Geode Capital Management LLC (1.14%). Insiders that own company stock include Ann M Hanly, Charles Elliott Sigal, Endurance (Cayman) Ltd Svf, George A Scangos, Herbert Virgin, Howard Horn, Janet Napolitano, Jay Parrish, Johanna Friedl-Naderer, Medpace Investors, Llc, Phillip Pang, Robert J More, Robert J More, Saira Ramasastry, Steven J Rice, Vicki L Sato and Vicki L Sato.
View institutional ownership trends.

Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VIR stock can currently be purchased for approximately $25.90.

Vir Biotechnology (NASDAQ:VIR) has a market capitalization of $3.47 billion and generates $1.62 billion in revenue each year. The company earns $515.84 million in net income (profit) each year or ($1.10) on an earnings per share basis.

The company employs 444 workers across the globe.

Vir Biotechnology's mailing address is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. The official website for the company is www.vir.bio. The company can be reached via phone at 415-906-4324 or via email at ir@vir.bio.